Last reviewed · How we verify
Tobramycin and dexamethasone
Tobramycin kills bacteria by inhibiting protein synthesis, while dexamethasone reduces inflammation and immune response in the eye.
Tobramycin kills bacteria by inhibiting protein synthesis, while dexamethasone reduces inflammation and immune response in the eye. Used for Bacterial conjunctivitis, Bacterial keratitis, Ocular inflammation associated with bacterial infection.
At a glance
| Generic name | Tobramycin and dexamethasone |
|---|---|
| Also known as | Tobradex |
| Sponsor | Bausch & Lomb Incorporated |
| Drug class | Antibiotic/corticosteroid combination |
| Target | Bacterial ribosome (tobramycin); glucocorticoid receptor (dexamethasone) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Tobramycin is an aminoglycoside antibiotic that binds to bacterial ribosomes and prevents protein synthesis, effectively killing susceptible gram-negative and gram-positive bacteria. Dexamethasone is a potent corticosteroid that suppresses inflammatory and immune responses by inhibiting phospholipase A2 and reducing production of inflammatory mediators. Together, they provide both antimicrobial and anti-inflammatory effects for ocular infections.
Approved indications
- Bacterial conjunctivitis
- Bacterial keratitis
- Ocular inflammation associated with bacterial infection
Common side effects
- Ocular irritation
- Conjunctival erythema
- Eye discomfort
- Lid edema
- Increased intraocular pressure (with prolonged use)
Key clinical trials
- Tobradex as Intracanal Medicament (NA)
- Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery (PHASE4)
- A Comparative Study Between Preservative With Benzalkonium Chloride vs Preservative Free Eye Drops on the Ocular Surface (PHASE4)
- VisuMax Femtosecond Laser Small Incision Lenticule Extraction for the Correction of High Myopia (NA)
- Platelet-rich Fibrin(PRF) Membrane in Ophthalmic Diseases (NA)
- Safety and Efficacy of Thermosensitive Hydroxybutyl Chitosan and 5-fluorouracil Assisted Endoscopic Dacryocystorhinostomy in the Treatment of Chronic Dacryocystitis (PHASE1)
- Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hypotensive Agents (PHASE4)
- Micro-Conjunctival Autografting Combined With Amniotic Membrane Transplantation Treating Recurrent Pterygium Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tobramycin and dexamethasone CI brief — competitive landscape report
- Tobramycin and dexamethasone updates RSS · CI watch RSS
- Bausch & Lomb Incorporated portfolio CI